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Pneumolysin is an important virulence factor of the human pathogen Streptococcus pneumoniae. Sequence
analysis of the ply gene from 121 clinical isolates of S. pneumoniae uncovered a number of alleles. Twenty-
two strains were chosen for further analysis, and 14 protein alleles were discovered. Five of these had been
reported previously, and the remaining 9 were novel. Cell lysates were used to determine the specific hemolytic
activities of the pneumolysin proteins. Six strains showed no hemolytic activity, and the remaining 16 were
hemolytic, to varying degrees. We report that the nonhemolytic allele reported previously in serotype 1,
sequence type (ST) 306 isolates is also present in a number of pneumococcal isolates of serotype 8 that belong
to the ST53 lineage. Serotype 1 and 8 pneumococci are known to be associated with outbreaks of invasive
disease. The nonhemolytic pneumolysin allele is therefore associated with the dominant clones of outbreak-
associated serotypes of S. pneumoniae.
Pneumolysin is a 53-kDa protein produced by most
clinical isolates of Streptococcus pneumoniae [1, 2] and
is an important virulence factor of the organism, which
is a causative agent of pneumonia, bacteremia, men-
ingitis, otitis media, and conjunctivitis in humans.
Pneumolysin is a cholesterol-dependent pore-forming
toxin and has lytic effects on many cell types. In ad-
dition to cell lysis, pneumolysin has a number of effects
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on host systems when present at sublytic levels [3–9],
including complement activation in the absence of anti-
pneumolysin antibodies and induction of proinflam-
matory mediators. Complement activation is indepen-
dent of the hemolytic activity of the toxin. Pneumolysin
has recently been shown to stimulate mouse macro-
phages to produce tumor necrosis factor–a and inter-
leukin-6 via interaction with Toll-like receptor (TLR)
4 and myeloid differentiation marker 88. This is also
independent of hemolytic activity [10]. Pneumolysin is
produced by the majority of pneumococci regardless
of serotype [1, 11], and toxoids are being considered
as vaccine candidates [12–14], either alone or as a car-
rier protein for the pneumococcal polysaccharides in
current vaccines.
The amino acid sequence of pneumolysin is thought
to be relatively conserved throughout all pneumococcal
serotypes with little variance over time and geographic
distance [15]. However, Lock et al. [16] have reported
that 2 isolates of serogroups 7 and 8 possess a threonine
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to isoleucine substitution at position 172. Both alleles also con-
tained a 2-aa deletion of valine 270 and lysine 271. Only the
T172I substitution affected the hemolytic activity of pneu-
molysin. Recently, data from our laboratory have shown that
serotype 1, sequence type (ST) 306 pneumococci produce a
nonhemolytic pneumolysin [17]. This allele contains all the
mutations reported for the serotype 8 strain by Lock et al. as
well as a tyrosine to histidine substitution at position 150 [17].
Serotype 1 pneumococci are unusual in being associated with
disease outbreaks [18–22]. The majority are linked to condi-
tions of overcrowding or alcoholism. In addition, serotype 1
pneumococci have a high attack rate and are rarely isolated
from nasopharyngeal carriage [23, 24]. Serotype 8 pneumococci
have also been associated with linked cases of disease [25].
Nonhemolytic pneumolysin has been previously observed in
serotype 1, ST306 isolates in our laboratory, and, hence, the
aim of the present study was to assess pneumolysin variation
and determine the distribution of pneumolysin alleles—in par-
ticular the nonhemolytic allele—in the serotype 1 pneumo-
coccal population. Because Lock et al. [16] have previously
described pneumolysin with reduced hemolytic activity in cer-
tain serotype 8 pneumococci, a similar analysis of pneumolysin
diversity within the serotype 8 population was undertaken.
MATERIALS AND METHODS
Bacterial strains, culture conditions, and sample preparation.
A list of strains used in the present study can be found in table
1. Pneumococcal strains were obtained from the Scottish Me-
ningococcal and Pneumococcal Reference Laboratory (SMPRL).
Pneumococci are received by SMPRL via an enhanced sur-
veillance scheme whereby 190% of isolates from persons with
invasive disease are received. These are serotyped and subjected
to multilocus sequence typing (MLST). Strains were also pro-
vided by R.C.G., A.B.B., and G.P. SMPRL isolates were chosen
to represent a wide range of serotypes, including those not
commonly isolated from persons with invasive disease, and to
be well distributed with respect to geographical location within
Scotland, disease type, and age of patient. Strains donated by
A.B.B. were representative of those used in a study of distri-
bution and diversity of serotype 1 pneumococci [23]. Strains
from Ghana represented the 3 most prevalent clones observed
[18]. Strains were grown in brain-heart infusion (BHI) broth
(Oxoid) and stored as frozen stocks on Protect beads (Technical
Service Consultants). Cells were grown in 50 mL of BHI broth
until midlogarithmic phase (OD600 between 0.55 and 0.65). Cell
lysates were prepared from 40 mL of culture, as described else-
where [17].
Measurement of pneumolysin activity. Pneumolysin con-
centration was determined using an ELISA, as described else-
where [17]. Hemolytic assays were performed as described else-
where [28], with modifications. First, 50 mL of 10 mmol/L
dithiothreitol was added before the addition of erythrocytes.
This was followed by a 30-min incubation at 37C. At the end
of the assay, 50 mL of PBS was added, and plates were centri-
fuged at 179 g in a bench-top centrifuge (model 4K15; Sigma)
for 1 min. One hundred microliters of supernatant was re-
moved, and the absorbance was measured at 540 nm.
The percentage of hemolysis and the log pneumolysin con-
centration were plotted against each other. The pneumolysin
concentration required to produce 50% lysis of erythrocytes
was determined. The reciprocal of this value gave the specific
activity, in hemolytic units (HU) per milligram, of the pneu-
molysin. Western blotting was done as described elsewhere [17].
DNA sequencing. Pneumococcal ply genes were amplified
by polymerase chain reaction (PCR) from gDNA preparations
using platinum Taq polymerase (Invitrogen) and primers 27R
and 27S, listed in table 2. PCR products were cleaned using
the AMPure PCR purification method (Agencourt Bioscience).
DNA sequencing was performed using Big Dye Terminator
cycle sequencing reagents (version 1.1; Applied Biosystems) and
a MegaBace 1000 DNA sequencer (Amersham). All primers are
shown in table 2. Full ply sequences were deposited in GenBank
under accession numbers EF413923–EF413960.
MLST analysis. e-BURST (version 2; http://www.mlst.net/)
was used to illustrate relationships between isolates listed in the
pneumococcal MLST database.
RESULTS
Sequence variation among pneumolysin genes. Partial DNA
sequences (data not shown) of ply genes from 121 strains were
aligned using the ClustalX interface (http://www.ebi.ac.uk/
clustalw/). Twenty-two isolates were chosen for further analysis,
because the others had pneumolysin alleles closely related to
the wild-type D39 strain. Variation in the DNA sequence oc-
curred at 37 positions in the pneumolysin of these isolates. The
DNA alleles were translated into protein sequences, and these
sequences were then aligned using ClustalX. Amino acid se-
quences showed variation at 15 positions, and 2 alleles contained
regions of insertion (figure 1). Five of the pneumolysin alleles
we identified had been previously reported [16, 17, 26, 27].
Alleles were aligned and numbered with the wild-type allele
(to which others were compared) being allele 1 (figure 1). This
allele is expressed by strain D39 and was the first pneumolysin
gene to be sequenced [26]. This protein had a specific activity
of HU/mg. Allele 2, present in strain TIGR4, had54.13 10
similar levels of hemolytic activity. Along with allele 1, allele 2
was the most common allele apparent in our initial screen.
Alleles 7, 9, 11, and 13 had similar specific activity and will
not be discussed further here.
Allele 3 was discovered in 2 serotype 8 isolates and is identical
Table 1. Strains used in the present study, by serotype and sequence type (ST)
and with pneumolysin allele and source detailed.
Strain Serotype ST
Pneumolysin
allele Source or reference
D39 2 128 1 Walker et al. [26]
TIGR4 4 205 2 Tettelin et al. [27]
S1_46 1 217 1 Brueggemann and Spratt [23]
P1041 1 217 2 Leimkugel et al. [18]
01_2696 1 227 2 Kirkham et al. [17]
S1_2 1 227 2 Brueggemann and Spratt [23]
00-3645 1 227 4 Kirkham et al. [17]
04-2055 1 228 5 SMPRL
S1-11 1 228 14 Brueggemann and Spratt [23]
INV1871 1 300 2 Brueggemann and Spratt [23]
P1039 1 303 1 Leimkugel et al. [18]
S1_8 1 303 2 Brueggemann and Spratt [23]
S1_4 1 304 2 Brueggemann and Spratt [23]
S1_30 1 305 2 Brueggemann and Spratt [23]
S1_3 1 306 5 Brueggemann and Spratt [23]
01-1956 1 306 5 Kirkham et al. [17]
S1_71 1 611 2 Brueggemann and Spratt [23]
S1_45 1 612 2 Brueggemann and Spratt [23]
P1021 1 612 2 Leimkugel et al. [18]
S1_125 1 613 1 Brueggemann and Spratt [23]
S1_126 1 614 1 Brueggemann and Spratt [23]
NCTC 7465 1 615 2 Brueggemann and Spratt [23]
S1_102 1 616 2 Brueggemann and Spratt [23]
S1_38 1 617 5 Brueggemann and Spratt [23]
S1_99 1 618 2 Brueggemann and Spratt [23]
03_5343 1 1239 5a SMPRL
03_5340 1 1310 5a SMPRL
04_1259 1 1311 5a SMPRL
04_1837 1 1346 5a SMPRL
04_2889 1 1597 5a SMPRL
05_1635 1 1809 5a SMPRL
05_1934 1 1882 5a SMPRL
01_2117 1 2126 5a SMPRL
96-5878 2 74 6 SMPRL
00-2328 6A 813 13 SMPRL
01-3862 7F 191 10 SMPRL
02-2744 7F 191 10 SMPRL
01-2884 8 53 5 SMPRL
2PN00495 8 404 3 Robert George (HPA)
01-1204 8 578 5 SMPRL
03_2331 8 835 5a SMPRL
H040920498 8 944 3 Robert George (HPA)
03_2620 8 1110 5a SMPRL
H034900039 8 1722 5a Robert George (HPA)
00-1153 9V 156 9 SMPRL
01-2513 18C 818 12 SMPRL
01-2914 20 591 11 SMPRL
01-2866 23F 40 8 SMPRL
01-4296 27 571 10 SMPRL
01-1199 NT 577 5 SMPRL
02-3013 NT 448 7 SMPRL
NOTE. HPA, Health Protection Agency; SMPRL, Scottish Meningococcal and Pneumococcal
Reference Laboratory.
a The ply gene was partially sequenced to determine the pneumolysin allele.
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Table 2. Primers used in DNA amplification and
sequencing of ply.
Primer DNA sequence (5′r3′)
27R CTTGGCTACGATATTGGC
27S TACTTGTCCAACCACGG
9Y CGGGATCCGGCAAATAAAGCA
4T GTTGATCGTGCTCCGATGA
4U TATACAGTCAGCGTAGACGC
4V CAATACAGAAGTGAAGGCGG
4W GATCATCAAGGTAAGGAAGTC
27T ATAAGTCATCGGAGCACG
15E TCCAACTTGAGATAGACTTGGCGCCC
5U GCTGTAACCTTAGTCTC
15C GGAGGTAGAAGATGGCAAATAAAGC
52R GAATTCCCTGTCTTTTCAAAGTC
PlyIntRev GGCAAGCCTGGATGATCTGCTG
to the Ply8 allele found in this serotype by Lock et al. [16].
This allele was shown to have reduced hemolytic activity and
reduced mobility on SDS-PAGE gel (data not shown), which
agreed with the findings of Lock et al.
Allele 4, which contains an 8 aa insertion/duplication at po-
sition 415, has been previously reported [17]. This allele was
found in a serotype 1, ST227 isolate and showed reduced he-
molytic activity, possibly due to insolubility of the protein [17].
Allele 5 was reported initially by Kirkham et al. [17] in se-
rotype 1, ST306 isolates. Here, we report this allele in serotype
8 clones of ST53 and related clones as well as in a nontypeable
ST577 isolate. Allele 5 is similar in sequence to allele 3 but has
an extra mutation at position 150. These alleles showed simi-
larly reduced mobility on SDS-PAGE gel. However, allele 5,
unlike allele 3, produces a nonhemolytic protein.
Allele 6, found in a serotype 2, ST74 isolate, was also similar
to allele 3 but had a further S167F mutation. This allele had
reduced hemolytic activity, resulting in a specific activity similar
to allele 3.
Both alleles 8 and 10 showed reduced hemolytic activity.
However, although allele 10 shares a number of mutations with
the nonhemolytic allele 5, allele 8 has only a single mutation
(A273D) compared with wild type. Allele 10 also shares with
alleles 3 and 5 reduced mobility on SDS-PAGE gel.
Allele 12 was present in a serotype 18C, ST818 isolate and
was not recognized by ELISA using the monoclonal antibody
PLY-7 [29], which recognizes amino acid positions 401–407 in
pneumolysin. Allele 12 is hemolytic, and Western blots using
polyclonal antibodies confirm that pneumolysin is expressed.
Nonrecognition using PLY-7 was also recently reported for a
number of alleles of the closely related cholesterol-dependent
cytolysin (CDC) mitilysin, although other alleles of this toxin
were recognized [28].
Allele 14 was discovered in serotype 1, ST228 strain S1-11,
isolated in Spain [23]. This allele is nonhemolytic and possesses
an insertion of 871 bp at amino acid position 142 in pneu-
molysin. Sequencing revealed the presence of the mobile genetic
element IS1515 [30] in a pneumolysin allele 2 background.
This is the first demonstration of a clinical isolate of S. pneu-
moniae not expressing pneumolysin. A second ST228 isolate
from invasive pneumococcal disease (IPD) in Scotland pos-
sessed allele 5 and no insertion.
eBURST analysis of the serotype 1 pneumococcal population.
A search of the MLST database for serotype 1 pneumococci
revealed 51 different STs of serotype 1. eBURST revealed the
presence of 4 major clusters (figure 2). These clusters cor-
responded to the 3 geographic lineages described by Bruegge-
mann and Spratt [23]. Lineage A, representing serotype 1 pneu-
mococci from Europe and North America, is split into 2 clonal
groups by eBURST. The predicted founders of these complexes
are ST306 and ST305. ST217 is the predicted founder of lineage
B, representing serotype 1 pneumococci from Africa and Israel,
and is also the predicted overall founder of the serotype 1
population. ST2296 is the predicted founder of lineage C. At
the time of the study by Brueggemann and Spratt [23], the
majority of isolates in lineage C were from Chile. However, this
lineage now contains isolates from a wider range of geograph-
ical locations.
Distribution of pneumolysin alleles within serotype 1 pneu-
mococci distinguished by ST. Because pneumolysin allele 5
has been shown to be present in all serotype 1, ST306 pneu-
mococcal isolates tested [17], it was of interest to determine
the distribution of this allele within the serotype 1 population.
Initially, ply genes from each of the 16 clones identified by
Brueggemann and Spratt [23] were fully sequenced. Nine of
these 16 strains were found to have allele 2, whereas 4 possessed
allele 1, 2 had the nonhemolytic allele 5, and 1 had allele 14.
The 2 isolates possessing allele 5 were clones of ST306 and
ST617, and the strain possessing allele 14 was ST228. This is
the first demonstration of allele 5 in serotype 1 strains other
than ST306. Figure 2 shows that ST306, ST617, and ST228 are
all present in lineage A. Because both hemolytic and nonhemo-
lytic alleles were present in this lineage, we obtained 8 more
lineage A isolates from SMPRL (figure 2). Partial sequencing
of these isolates was used to determine the pneumolysin allele
identity. This revealed that all single-locus variants of ST306
tested in lineage A possess the nonhemolytic allele 5 as well as
2 double-locus variants, for a total of 9 serotype 1 STs shown
to possess allele 5. The ply genes from 3 serotype 1 strains
representing the dominant STs from recent meningitis out-
breaks in Ghana (ST217, ST303, and ST612) [18] were also
sequenced. These STs were also present in the data set of Brueg-
gemann and Spratt [23]. ST217, the predicted founder of lin-
eage B, is associated with both pneumolysin alleles 1 and 2.
Similarly, in lineage A ST228 is associated with 2 pneumolysin
alleles (alleles 5 and 14), as is ST227 (alleles 2 and 4). This is
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Figure 1. Pneumolysin alleles determined by full sequencing of ply genes from 22 isolates. The nos. in the first row refer to amino acid positions,
with the identity of the wild-type amino acid shown in the second row. The mutated amino acids present in specific strains are highlighted in black
below the corresponding wild-type amino acid. Strains highlighted in black are nonhemolytic and as such have a specific activity of 0. Insertion regions
(INS) are highlighted in gray. Deletion of an amino acid is represented by the abbreviation DEL. Specific activity is shown in hemolytic units per
milligram. The lysate of strain 01-2513 (allele 12) was hemolytic but was not recognized by the monoclonal antibody PLY-7; therefore, no specific
activity was determined. The lysate of strain 00-3645 (allele 4) was hemolytic but at a level that did not allow calculation of specific activity. ST,
sequence type.
the first demonstration of intra-ST amino acid variation within
pneumolysin. Results of hemolytic assays done on lysates of all
strains sequenced were in agreement with the hemolytic profiles
previously observed for these alleles.
Distribution of pneumolysin alleles within serotype 8 pneu-
mococci distinguished by ST. Having observed pneumolysin
allele 5 in 2 serotype 8 strains, an eBURST diagram was created
for serotype 8 strains present in the MLST database, and isolates
of this serotype available from SMPRL were partially sequenced
to determine pneumolysin allele identity. eBURST identified
ST53 as the predicted founder clone of serotype 8 pneumococci.
This clone had pneumolysin allele 5. The 4 other STs available
from the main clonal complex also had this pneumolysin allele
(figure 3). There were 2 strains that possessed allele 3, identical
to the Ply8 allele identified in serotype 8 pneumococci by Lock
et al. [16]. These clones were predicted founders of the 2 other
main clonal complexes shown by this eBURST diagram (fig-
ure 3).
Prevalence of serotype 8–related IPD in Scotland. To ex-
amine whether ST53 had been undergoing clonal expansion
similar to that detailed for ST306 by Kirkham et al. [17], in-
formation from SMPRL was used to determine the prevalence
of serotype 8–related IPD during the last 4 years in Scotland.
The prevalence of ST53-related IPD within this serotype was
also assessed. Serotype 8–related IPD has not been increasing
significantly in Scotland. Approximately 5% of IPD isolates
were serotype 8 in 2002–2005. ST53 is already established as
the dominant clone within the Scottish serotype 8 population,
representing 180% of serotype 8 isolates from 2002–2005 (data
not shown).
DISCUSSION
Fourteen pneumolysin alleles were identified in this study. Pre-
viously, pneumolysin was considered to be a well-conserved
protein [15]; however, 6 pneumolysin alleles had been previ-
ously reported. Here, we report the presence of 9 more novel
pneumolysin alleles. The existence of at least 15 pneumolysin
proteins shows that variation at the amino acid level is greater
than previously thought. Pneumolysin shows a sequence var-
iation of 3.3%. This is slightly higher than pneumococcal
housekeeping genes, which show levels of sequence divergence
ranging from 1% to 2% [31]. Large amounts of variation have
been observed in pneumococcal surface proteins (e.g., PspC
[32, 33] and NanA [34, 35]) and in antibiotic-resistance de-
terminants, such as penicillin-binding protein genes. Variation
in these proteins is thought to be due to evolutionary pressure
from the host immune system or from antibiotic use [36, 37].
However, the selective evolutionary pressure on pneumolysin
is unknown. The allelic variation observed here results in the
expression of nonhemolytic pneumolysin in certain clonal
groups of pneumococci, namely lineages of serotype 1 and
serotype 8 pneumococci. Nonhemolytic pneumolysin was also
observed in a nontypeable strain related by ST to clones of
serotype 8 (allele 5). Because the nontypeable strain shares both
pneumolysin and housekeeping alleles with serotype 8 pneu-
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Figure 2. eBURST diagram showing the relationship between serotype 1 clones of Streptococcus pneumoniae as well as the distribution of
pneumolysin alleles within the serotype 1 pneumococcal population.
mococci, it is possible that the isolate has serotype 8 capsule
genes that are not expressed or that there is partial or full
deletion of capsular genes. Given that pneumolysin alleles often
correlate with the ST and the serotype of a pneumococcus, we
hypothesize that the pressure to maintain alternative pneu-
molysin alleles stems from the pneumococcal genome itself,
suggesting that certain pneumolysin alleles will be maintained
only when present alongside a certain set of other pneumo-
coccal proteins and that all of the proteins present in the set
are required to work in concert to ensure the survival of the
clone.
PLY-7 is currently used in an ELISA in many laboratories to
determine presence or absence of pneumolysin [38]. However,
the discovery of allele 12 indicates that there may be instances
of false-negative results in such tests. The detection of the re-
lated CDC mitilysin by use of this antibody indicates that false-
positive results are also possible [28]. Therefore, care should
be taken when interpreting results obtained using this antibody
as a diagnostic or therapeutic tool. Allele 12 was found in a
serotype 18C, ST818 isolate. This serotype is included in the
PCV7 pneumococcal conjugate vaccine; however, this isolate
is the only representative of this ST in the MLST database.
When eBURST was used to analyze all strains of serogroup 18/
serotype 18C, ST818 was not found to be part of the major
serotype 18C clonal complex.
Isolate S1-11, possessing pneumolysin allele 14, was shown
to be negative for expression of pneumolysin. This result is of
interest, because S1-11 was isolated from a patient with pneu-
monia, implying disease-causing ability without pneumolysin
expression. S1-11 represents the first demonstration of a pneu-
mococcal clinical isolate that fails to produce pneumolysin. The
insertion of 871 bp present in this allele encodes IS1515, a
functional insertion sequence present predominantly in sero-
type 1 pneumococci [39]. Because IS1515 contains internal
promoter regions, expression and therefore excision of the in-
sertion sequence may still be possible. S1-11 is a blood isolate,
demonstrating the ability to progress from the lungs into the
blood. IS1515 is an active mobile element that is capable of
excision and insertion elsewhere in the genome. It is therefore
possible that this strain produced a functional pneumolysin at
the time the isolate established disease.
Distribution of pneumolysin allele 5 within the serotype 1
pneumococcal population is not confined to ST306 itself, al-
though it is found only in the ST306 clonal complex. There
appears to be a split in pneumolysin identity in lineage A.
Although this correlates with ST to some extent, pneumolysin
allele 2 is found in both branches. The 2 alleles are unrelated,
varying by 17 nt that results in 7 aa changes. The 2 branches
of lineage A are linked, as their founders are triple-locus variants
of one another.
Pneumolysin allele 5 is also present in serotype 8 pneumo-
cocci. This allele is present only in the main clonal complex of
this serotype (the ST53 complex). In contrast to SLVs of ST306
present in the MLST database, which are solely Scottish isolates,
the SLVs of ST53 submitted to the database are from varying
geographical locations. The prevalence data presented showed
that ST53 is already the dominant clone in serotype 8–related
IPD in Scotland. This is in contrast to published data on ST306
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Figure 3. eBURST diagram showing the relationship between serotype 8 clones of Streptococcus pneumoniae as well as the distribution of
pneumolysin alleles within the serotype 8 pneumococcal population.
prevalence in serotype 1–related IPD [17], which shows on-
going clonal expansion of ST306 to become the dominant clone
in this serotype. These results, together with the observed geo-
graphical spread of ST53-related clones, allow us to hypothesize
that allele 5 may have been present in ST53 before being ac-
quired by ST306 pneumococci. Allele 5 may then facilitate
clonal expansion of pneumococci. However, we appreciate that
the nature of the MLST database means that internationally
disseminated clones of the ST306 complex may exist.
There appears to be a relationship between the mutations
carried by alleles 3, 5, and 10 and the electophoretic mobility
of these proteins in SDS-PAGE. Proteins of these alleles have
reduced mobility and so have an apparently higher molecular
weight [16]. These alleles share the mutation A265S and the
deletion of amino acids at positions 270 and 271. These may
be responsible for the reduced mobility; however, allele 6 also
possesses these mutations and shows no reduced mobility, al-
though it has a further S167F mutation that may affect mobility
(data not shown).
ST53 and ST306 are unrelated, sharing only 1 housekeeping
allele (spi). Furthermore, the sequences of the other house-
keeping alleles are no more similar than those of 2 random
clones (data not shown). This shows that there is no obvious
relation between the 2 predicted founders of the clonal com-
plexes associated with allele 5.
Y150H is the only mutation unique to the nonhemolytic
allele 5. The tyrosine at this position was found to be fully
conserved among all CDCs, whereas other positions of mu-
tation in pneumolysin were shown to vary among CDCs (data
not shown). This suggests an importance of this residue in the
hemolytic activity of these toxins. Purified toxin possessing only
the mutation Y150H has hemolytic activity of 478 HU/mg,
implying that, although this mutation severely depletes he-
molytic activity, the other mutations are also required to ab-
rogate the activity of the toxin.
Unlike pneumococci of most other serotypes, serotype 1
pneumococci are known to be associated with outbreaks of
pneumococcal disease. Serotype 8 pneumococci have also been
responsible for such outbreaks [25, 40]. In the present study
of 121 pneumococcal isolates, nonhemolytic pneumolysin var-
iants were found only in serotypes that have been associated
with outbreak disease. We propose that there is an association
between nonhemolytic pneumolysin and pneumococcal sero-
types that are able to cause outbreaks. Although hemolytic ac-
tivity may not be required for IPD, other activities of the variant
toxins (e.g., complement activation and inflammation via in-
teraction with TLR4) may contribute to the pathogenesis of
infection. Whether there is a causal link between expression of
nonhemolytic toxin and outbreaks will require a much larger
study comparing outbreak and nonoutbreak isolates. Given that
outbreaks of pneumococcal disease remain rare, such a study
may prove to be difficult.
In conclusion, pneumolysin has a level of variation higher
than previously thought, and the lytic activity of the toxin is
not always required for IPD. Furthermore, we report the pres-
ence of an insertion sequence that abrogates pneumolysin ex-
pression in a clinical isolate. These findings imply that the roles
played by pneumolysin may vary in pneumococci of different
genetic backgrounds. Nonhemolytic alleles appear to be con-
fined to certain unrelated clonal complexes that have under-
gone expansion. We propose that this property of pneumolysin
in certain genetic backgrounds can play a role in driving such
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clonal expansion and may have an involvement in outbreaks
of pneumococcal disease.
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